<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893825</url>
  </required_header>
  <id_info>
    <org_study_id>TV46000-CNS-30078</org_study_id>
    <secondary_id>2019-000063-24</secondary_id>
    <nct_id>NCT03893825</nct_id>
  </id_info>
  <brief_title>A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia</brief_title>
  <official_title>A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the long-term safety and tolerability of&#xD;
      TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse&#xD;
      events, including serious adverse events. For new patients, the total duration of patient&#xD;
      participation in the study is planned to be up to 80 weeks (including a screening period of&#xD;
      up to 4 weeks, a 12-week oral conversion/stabilization stage [Stage 1], a 56-week&#xD;
      double-blind maintenance stage [Stage 2], and a follow-up period [8 weeks]). For roll-over&#xD;
      patients, the total duration of patient participation in the study is planned to be up to 64&#xD;
      weeks (including up to 56 weeks in the maintenance stage [Stage 2] and a follow-up period [8&#xD;
      weeks]). Patients who started Stage 2 who relapse or meet 1 or more of the withdrawal&#xD;
      criteria should be invited to perform the Early Termination visit as soon as possible within&#xD;
      4 weeks of the last injection. Patients who withdraw from the study before completing the&#xD;
      56-week maintenance stage will have follow-up procedures and assessments performed at their&#xD;
      follow-up visits. During the follow-up period, patients will be treated according to the&#xD;
      investigator's judgment.&#xD;
&#xD;
      All subjects will be treated with active drug.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events including serious adverse events</measure>
    <time_frame>Week 56</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Number of participants who withdraw due to adverse events</measure>
    <time_frame>Week 56</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">336</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>TV-46000 - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46000 - B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46000</intervention_name>
    <description>subcutaneous (sc) injection</description>
    <arm_group_label>TV-46000 - A</arm_group_label>
    <arm_group_label>TV-46000 - B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>TV-46000 - B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072:&#xD;
&#xD;
          -  The patient must have participated in the pivotal efficacy study (Study&#xD;
             TV46000-CNS-30072) without experiencing relapse events and without important protocol&#xD;
             deviations.&#xD;
&#xD;
          -  If the patient was taking antidepressants or mood stabilizers in Study&#xD;
             TV46000-CNS-30072, no dose changes or initiation of treatment with these medications&#xD;
             will be permitted.&#xD;
&#xD;
          -  The patient, in the investigator's judgment, requires chronic treatment with an&#xD;
             antipsychotic medication.&#xD;
&#xD;
          -  The patient is able to understand the nature of the study and follow protocol&#xD;
             requirements, including the prescribed dosage regimens (oral and sc administration)&#xD;
             and non-use of prohibited concomitant medications; can read and understand the written&#xD;
             word in order to complete patient-reported outcomes measures; and can be reliably&#xD;
             rated on assessment scales.&#xD;
&#xD;
          -  The patient has had a stable place of residence for the previous 3 months before the&#xD;
             baseline visit in this study, and changes in residence are not anticipated over the&#xD;
             course of study participation.&#xD;
&#xD;
          -  The patient has no significant life events (such as pending loss of housing, family&#xD;
             status change, long travel abroad, surgery, etc) that could affect study outcomes&#xD;
             expected throughout the period of study participation.&#xD;
&#xD;
          -  Women of childbearing potential and sexually active female adolescents must agree not&#xD;
             to try to become pregnant, and, unless they have exclusively same-sex partners, must&#xD;
             agree to use a highly effective method of contraception and agree to continue use of&#xD;
             this method beginning 1 month before the first administration of study drug and for&#xD;
             the duration of the study and for 120 days after the last injection of study drug.&#xD;
&#xD;
          -  The patient, if adult or adolescent male, is surgically sterile, or, if capable of&#xD;
             producing offspring, has exclusively same-sex partners or is currently using an&#xD;
             approved method of birth control and agrees to the continued use of this method for&#xD;
             the duration of the study (and for 120 days after the last dose of study drug). Male&#xD;
             patients with sex partners who are women of childbearing potential must use condoms&#xD;
             even if surgically sterile. In addition, male patients may not donate sperm for the&#xD;
             duration of the study and for 120 days after taking the study drug.&#xD;
&#xD;
        New Patients (Not Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072):&#xD;
&#xD;
          -  The patient has a diagnosis of schizophrenia&#xD;
&#xD;
          -  The patient has been responsive to an antipsychotic treatment (other than clozapine)&#xD;
             in the past year based on investigator judgment (and discussions with family members,&#xD;
             caregivers, or healthcare professionals as applicable).&#xD;
&#xD;
          -  The patient, in the investigator's judgment, requires chronic treatment with an&#xD;
             antipsychotic medication.&#xD;
&#xD;
          -  The patient is able to understand the nature of the study and follow protocol&#xD;
             requirements, including the prescribed dosage regimens (oral and sc administration)&#xD;
             and non-use of prohibited concomitant medications; can read and understand the written&#xD;
             word in order to complete patient-reported outcomes measures; and can be reliably&#xD;
             rated on assessment scales.&#xD;
&#xD;
          -  The patient has had a stable place of residence for the previous 3 months before&#xD;
             screening, and changes in residence are not anticipated over the course of study&#xD;
             participation.&#xD;
&#xD;
          -  The patient has no significant life events (such as pending loss of housing, family&#xD;
             status change, long travel abroad, surgery, etc) that could affect study outcomes&#xD;
             expected throughout the period of study participation.&#xD;
&#xD;
          -  The patient has a body mass index between 18.0 and 38.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Women of childbearing potential and sexually active female adolescents must agree not&#xD;
             to try to become pregnant, and, unless they have exclusively same-sex partners, must&#xD;
             agree to use a highly effective method of contraception and agree to continue use of&#xD;
             this method beginning 1 month before the first administration of study drug and for&#xD;
             the duration of the study and for 120 days after the last injection of study drug.&#xD;
&#xD;
          -  The patient, if adult or adolescent male, is surgically sterile, or, if capable of&#xD;
             producing offspring, has exclusively same-sex partners or is currently using an&#xD;
             approved method of birth control and agrees to the continued use of this method for&#xD;
             the duration of the study (and for 120 days after the last dose of study drug). Male&#xD;
             patients with sex partners who are women of childbearing potential must use condoms&#xD;
             even if surgically sterile. In addition, male patients may not donate sperm for the&#xD;
             duration of the study and for 120 days after taking the study drug.&#xD;
&#xD;
          -  Additional criteria apply, please contact the investigator for more information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072:&#xD;
&#xD;
          -  The patient has a finding in the baseline 12-lead ECG that is considered clinically&#xD;
             significant in the judgment of the investigator.&#xD;
&#xD;
          -  Poor compliance with study procedures (in the opinion of the investigator or sponsor)&#xD;
             during the pivotal efficacy Study TV46000-CNS-30072. This should be discussed on a&#xD;
             case-by-case basis.&#xD;
&#xD;
        New Patients (Not Rolling Over from the Pivotal Efficacy Study TV46000-CNS-30072) and&#xD;
        Roll-Over Patients:&#xD;
&#xD;
          -  The patient is currently on clozapine or has received electroconvulsive therapy in the&#xD;
             last 12 months.&#xD;
&#xD;
          -  The patient has a history of epilepsy or seizures, neuroleptic malignant syndrome,&#xD;
             tardive dyskinesia, or other medical condition that would expose the patient to undue&#xD;
             risk.&#xD;
&#xD;
          -  The patient has a positive serology for human immunodeficiency virus (HIV)-1, HIV-2,&#xD;
             hepatitis B surface antigen, and/or hepatitis C.&#xD;
&#xD;
          -  The patient has current or a history of known hypersensitivity to risperidone or any&#xD;
             of the excipients of TV-46000 or the oral formulation of risperidone used in the&#xD;
             stabilization phase.&#xD;
&#xD;
          -  The patient has a substance use disorder, including alcohol and benzodiazepines but&#xD;
             excluding nicotine and caffeine.&#xD;
&#xD;
          -  The patient is a pregnant or lactating female.&#xD;
&#xD;
          -  The patient has used an investigational drug other than TV-46000 within 3 months prior&#xD;
             to screening or has participated in a non-drug clinical trial within 30 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Vulnerable patients (eg, people kept in detention).&#xD;
&#xD;
          -  Additional criteria apply, please contact the investigator for more information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 14391</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14401</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14405</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14796</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14811</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14794</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14776</name>
      <address>
        <city>Colton</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14802</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14773</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14774</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14817</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <zip>90631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14771</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14863</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14816</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14786</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14827</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056-4515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14777</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14815</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14785</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14818</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14788</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14783</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14865</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14787</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14814</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14861</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14390</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14799</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14389</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14875</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14400</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14832</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14810</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14860</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14396</name>
      <address>
        <city>W. Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14821</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14770</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14415</name>
      <address>
        <city>Norcross</city>
        <state>Georgia</state>
        <zip>30093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14829</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14805</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14871</name>
      <address>
        <city>Lincolnwood</city>
        <state>Illinois</state>
        <zip>60712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14862</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14869</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14866</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14764</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14791</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14813</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14826</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14809</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14414</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14792</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14772</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14876</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14780</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14867</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14416</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14763</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14782</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14859</name>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14793</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14778</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14868</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14801</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14807</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14393</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14856</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14395</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59148</name>
      <address>
        <city>Bourgas</city>
        <zip>8000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59152</name>
      <address>
        <city>Kazanlak</city>
        <zip>6100</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59151</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59149</name>
      <address>
        <city>Novi Iskar</city>
        <zip>1282</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59144</name>
      <address>
        <city>Sofia</city>
        <zip>1680</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59154</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59150</name>
      <address>
        <city>Varna</city>
        <zip>9020</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 59146</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11171</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11169</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 2J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11173</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11170</name>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <zip>N7L 1C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11174</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35259</name>
      <address>
        <city>Clermont Ferrand Cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35257</name>
      <address>
        <city>Douai</city>
        <zip>59500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35260</name>
      <address>
        <city>Nice cedex 1</city>
        <zip>6002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35256</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80162</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80161</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80156</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80155</name>
      <address>
        <city>Hod Hasharon</city>
        <zip>4534708</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80157</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262160</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80160</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

